Treatment for Higher Risk MDS
Summary of FDA-approved medicines for treating high risk MDS and transplantation options
Myelodysplastic Syndromes (MDS)
Treatment for Lower Risk MDS
Summary of active surveillance and supportive care MDS treatment options
Understanding the Symptoms of MDS
Review of the range of MDS symptoms based on low blood counts
Knowing Your MDS Risk Level
Explanation of how and why your MDS risk level determines your treatment options
What is MDS
Basic description of MDS and how it affects your bone marrow and blood
Order Patient Educational Materials
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure
Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome
Original Publication Date
Article Source
External Web Content
Summary Many veterans and doctors have long questioned whether Agent Orange (AO) exposure during the Vietnam War contributed to cases of myelodysplastic syndrome (MDS), a type of blood cancer. The contaminated chemical is linked to several cancers, but a link to MDS was unclear…
Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia
Original Publication Date
Article Source
External Web Content
Abstract Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP) and progression to myelodysplastic syndromes (MDS). Using single-cell and anatomical profiling of a large cohort of human bone marrow (BM)…
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy
Original Publication Date
Article Source
External Web Content
Key Points Ivosidenib, venetoclax ± azacitidine either rapidly selects evolved, resistant leukemic clones or eradicates leukemic clones. Resistant clones express RNA signatures of stemness, branched-chain amino acid metabolism, and menin targets. Subjects:Myeloid Neoplasia…
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry
Infections are an important cause of morbidity and mortality in patients with lower-risk myelodysplastic syndromes myelodysplastic syndromes: